# Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection

> **NCT00739934** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 40 (actual)

## Conditions studied

- Candidiasis
- Candidemia

## Interventions

- **DRUG:** voriconazole (Vfend)

## Key facts

- **NCT ID:** NCT00739934
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2011-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00739934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00739934, "Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00739934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*